Free Trial
NASDAQ:ELDN

Eledon Pharmaceuticals Q4 2024 Earnings Report

Eledon Pharmaceuticals logo
$2.99 -0.01 (-0.33%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$2.98 -0.01 (-0.17%)
As of 04/17/2025 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eledon Pharmaceuticals EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.32
Beat/Miss
Missed by -$0.32
One Year Ago EPS
-$1.00

Eledon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eledon Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 20, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Eledon Pharmaceuticals' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Eledon Pharmaceuticals Earnings Headlines

The U.S. just rewrote the rules of retirement
For decades, Wall Street told retirees to stick with big names, stay diversified, and live off dividends. But Tim Plaehn says those rules no longer apply — and the 2025 trade war is exposing just how fragile that plan really was. Tim just released a video briefing explaining how the global shift is hammering traditional income stocks — and how a few U.S.-focused companies are built to weather the chaos.
Guggenheim Remains a Buy on Eledon Pharmaceuticals (ELDN)
See More Eledon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

View Eledon Pharmaceuticals Profile

More Earnings Resources from MarketBeat